Clarivate Appoints Michael Easton as Chief Financial Officer
Key Executive Transition Announced
Clarivate Plc (NYSE: CLVT), a global leader in transformative intelligence solutions, announced a significant leadership change with the appointment of Michael Easton as Executive Vice President and Chief Financial Officer (CFO), effective August 8, 2026. Easton succeeds Jonathan Collins, who is stepping down as CFO to pursue another opportunity.
Highlights of the Announcement
- Leadership Change: Michael Easton, previously Senior Vice President and Chief Accounting Officer, takes over as CFO after a long tenure with Clarivate, bringing over 25 years of financial and operational experience.
- Strategic Focus: As CFO, Easton will prioritize accelerating growth, improving profitability, strengthening free cash flow generation, and maintaining disciplined capital allocation.
- Succession Planning: The transition highlights Clarivate’s commitment to robust succession planning within its senior leadership team.
- Market-Relevant Accomplishments: Easton was instrumental in strengthening financial discipline, enhancing governance and controls, and driving operational excellence across the company.
- Departing CFO’s Legacy: Jonathan Collins is credited for bringing rigor to financial management and supporting strategic initiatives, including the planned divestiture of Clarivate’s Life Sciences & Healthcare segment.
- Second Quarter 2026 Financial Results: The announcement coincides with the release of Q2 2026 financial results, with a webcast scheduled for investors and stakeholders. The company signals the webcast may include forward-looking information.
Potentially Price-Sensitive Information for Shareholders
- Leadership Stability and Strategic Execution: The appointment of a highly experienced internal candidate as CFO – especially someone with intimate knowledge of the company’s operations and strategic priorities – can reassure the market and support continued execution of growth plans.
- Divestiture Activity: The reference to the planned divestiture of the Life Sciences & Healthcare segment is noteworthy, as such restructuring could impact the company’s future growth profile, balance sheet, and capital allocation decisions. Investors should monitor developments around this divestiture.
- Operational Focus: The new CFO’s mandate to improve profitability, cash flow, and capital discipline could drive value creation and may influence share price performance, especially if followed by tangible financial improvements.
- Forward-Looking Statements: The company’s communication includes forward-looking statements regarding growth, profitability, capital allocation, and the impact of artificial intelligence (AI) on business strategy. These indicate ongoing transformation efforts and possible updates to guidance or outlook that could affect investor sentiment.
Background on Michael Easton
Michael Easton brings deep experience in finance and accounting to his new role. At Clarivate, he has overseen global controllership, financial reporting, treasury, and corporate FP&A functions. Prior to Clarivate, Easton was Senior Vice President, Financial Planning and Analysis at IHS Inc., and subsequently Senior Vice President and Chief Accounting Officer at IHS Markit, where he led global accounting, reporting, and finance operations post-merger. Earlier in his career, Easton spent over 14 years with Ernst & Young in various assurance roles. He holds bachelor’s and master’s degrees in accounting from Brigham Young University and is a Certified Public Accountant.
Statements from Leadership
Matti Shem Tov, CEO, commented: “Michael is a highly respected leader whose financial expertise, strategic insight, and institutional knowledge will be invaluable in sustaining our momentum and advancing our growth strategy. His appointment underscores the strength of our leadership bench and our commitment to thoughtful succession planning. I am confident he will help us deliver sustainable growth and long-term shareholder value.”
Michael Easton, incoming CFO, said: “I am honored to serve as EVP and CFO and appreciate the confidence Matti and our Board have placed in me. Clarivate has a strong foundation, an exceptional team, and significant opportunities ahead. My focus will be on disciplined execution—building on our momentum, working across the Company to accelerate growth, and translating our strategic priorities into lasting value for our customers and shareholders.”
On Jonathan Collins’ Departure: “We appreciate Jonathan’s many contributions to Clarivate during an important transformation period. He brought rigor to our financial management and execution and translated key strategic initiatives and priorities into action, including the planned divestiture of our Life Sciences & Healthcare segment. We wish him every success in the future.”
Upcoming Investor Event
Clarivate will host a conference call and webcast to discuss its Q2 2026 financial results and provide additional context on these management changes. The webcast is open to all interested parties and will include forward-looking commentary.
About Clarivate
Clarivate is a global provider of enriched data, insights & analytics, workflow solutions, and expert services in Academia & Government, Intellectual Property, and Life Sciences & Healthcare.
For more information, visit www.clarivate.com.
Contacts
- Media: Amy Bourke-Waite, Senior Director, Communications & Brand, [email protected]
- Investor Relations: Mark Donohue, Vice President, Investor Relations, [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to various risks and uncertainties, which may cause actual results to differ materially from those expressed or implied. Investors should consult official filings and company announcements for further information.
